esophageal cancer Newly Public Lucid Diagnostics Posts $200K in Preliminary Q3 Revenues The company's revenues were derived from its EsoGuard Esophageal DNA Test for esophageal cancer and related cell-collection device. BTIG, Canaccord Genuity Initiate Coverage of Lucid Diagnostics With Buy Ratings BTIG and Canaccord Genuity said Lucid's products have a total addressable market similar to that of Exact Sciences' Cologuard colorectal cancer screening test. Castle Biosciences Buy of Cernostics Aligns With Goal to Diversify Portfolio Premium The acquisition of Cernostics and its TissueCypher Barrett's Esophagus Assay provides a route for Castle to enter gastrointestinal testing. Castle Biosciences Acquires Cernostics for up to $80M Cernostics specializes in spatial biology and artificial intelligence-driven image analysis of tissue biopsies. Lucid Diagnostics Prices $70M IPO, Starts Trading on Nasdaq Lucid markets an esophageal DNA test and cell collection device for the detection of gastroesophageal reflux disease, and esophageal precancer and cancer. Jul 13, 2021 Gastric Cancer Cases Frequently Harbor Genetic Risk Variants, Suggesting Germline Testing Jun 10, 2021 Lucid Diagnostics Obtains CE Mark for Esophageal Cancer Molecular Test Feb 18, 2021 Stella Diagnostics, Mayo Clinic Collaborating on Barrett's Esophagus Protein Markers Oct 12, 2020 Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test Sep 24, 2020 Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test Sep 8, 2020 Early Copy Number Changes Predict Progression of Barrett's Esophagus to Esophageal Cancer Aug 6, 2020 PavMed Raises $7M in Private Funding Round Jul 1, 2020 AnchorDx Demonstrates Liquid Biopsy DNA Methylation Test for Early Cancer Detection Premium May 11, 2020 Genetic Ancestry Linked to Differences in Molecular Features of Cancers Apr 8, 2020 Esophageal Cancer Case Study Suggests Utility as Clinicians Explore Expanded Uses for Liquid Biopsy Premium Feb 25, 2020 Capsulomics, Johns Hopkins Partner on Esophageal Cancer, Barrett's Esophagus Research Feb 20, 2020 Lucid Diagnostics, Fred Hutchinson Cancer Research Center Ink Esophageal Cancer Biomarker Deal Feb 13, 2020 Lucid Diagnostics EsoGuard DNA Test Gets FDA Breakthrough Device Status Jan 6, 2020 Interpace Biosciences, University of North Carolina Launch Barrett's Esophagus Study Aug 13, 2019 Interpace Diagnostics Q2 Revenues Climb 14 Percent May 8, 2019 Almac Assay's Ability to Stratify Esophageal Cancer Patients Demonstrated by UK Researchers Premium Feb 11, 2019 Johns Hopkins Team to Commercialize Barrett's Esophagus Epigenetic Biomarker Panel Premium Feb 4, 2019 Esophageal Cancer Analysis Reveals Driver, Prognostic Alterations Jan 2, 2019 Cancer Driver Gene Mutations Rise with Age in Otherwise Normal Esophageal Tissue Nov 13, 2018 Interpace Diagnostics Q3 Revenues Up 38 Percent Load More Breaking News Epic Sciences, Biosplice Therapeutics Partner on Multiomic Profiling for Cancer Trials Hamilton, Pacific Biosciences Partner on Automating DNA Sample Prep Danaher Q4 Revenues Rise 21 Percent COVID-19 Severity Biomarker Candidates Revealed in RNA Sequencing Study Flatiron Health, Japanese Hospital Partner on Real-World GI Cancer Database Abbott Q4 Diagnostics Revenues Grow 3 Percent, Full-Year Revenues up 25 Percent The Scan Time to Act A new report urges the UK to consider regulations to protect against the misuse of genomic technologies, according to the Guardian. Fulgent Seeking Defamation Suit Fulgent Genetics says it plans to sue Los Angeles County Sheriff Alex Villanueva for defamation, the Los Angeles Times reports. Speeding Gene-Edited Crops Reuters reports that China's new trial rules will make it easier to grow gene-edited crops there. Nucleic Acids Research Papers on Viral Recombination, Pan-Cancer Mutations, SARS-CoV-2 Variability In Nucleic Acids Research this week: updated pipeline to detect viral recombination, mutational patterns in tumor samples, and more.